NewsBenzingaEloxx Pharmaceuticals Finalizes Design For Its EXPRESS Phase 2 Global Trial In Nonsense-Mutation Autosomal Dominant Polycystic Kidney Disease To Enrolol 60 Adults With Genetically Confirmed PKD1 Or PKD2 Nonsense Mutations Eloxx Pharmaceuticals Finalizes Design For Its EXPRESS Phase 2 Global Trial In Nonsense-Mutation Autosomal Dominant Polycystic Kidney Disease To Enrolol 60 Adults With Genetically Confirmed PKD1 Or PKD2 Nonsense Mutations Benzinga 2026.10.20 13:36 (GMT+0) Open on Benzinga Other news Truist Securities Maintains Hold on M&T Bank, Lowers Price Target to $235 Truist Securities Maintains Buy on Inspired Entertainment, Lowers Price Target to $8 Truist Securities Maintains Buy on Gartner, Raises Price Target to $235 Wintrust Financial Q3 2026 Earnings Call Transcript MSCI Jumps After Q3 Revenue Beat Led by Its Index Business Steel Dynamics Q3 2026 Earnings Call Transcript
